VACCITECH PLC
Barinthus Biotherapeutics plc is a clinical-stage biopharmaceutical company focused on developing immunotherapeutic candidates for treating autoimmune and inflammatory diseases. The Company’s pipeline, built around platform technologies; viral vector-based, consists of ChAdOx and MVA, and synthetic, consisting of SNAP-Tolerance Immunotherapy (SNAP-TI). These platforms help to develop antigen-specific immunotherapeutic candidates designed to optimize the disease fighting capabilities of T cells. It is focused on developing two product candidates that harness its viral vector and synthetic platform technologies. These include VTP-300, a Phase II immunotherapeutic candidate designed as a potential component of a functional cure for chronic hepatitis B virus infection utilizing ChAdOx/MVA, and VTP-1000, its autoimmune candidate designed to utilize the SNAP-TI platform to treat patients with celiac disease. The Company's pipeline also includes VTP-850, VTP-500 and VTP-400.
Stock Performance Snapshot
Analyst Rating
Analysts recommend buying VACCITECH PLC's stock with a target price of $5.4, indicating growth potential.
Financial Health
Vaccitech is producing decent revenue and cash flow, with solid value per share indicating stability.
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Baskets Featuring BRNS
Analyst All-Stars
Take advantage of Wall Street's collective wisdom with this portfolio of top-rated stocks. These companies have earned strong 'Buy' ratings from respected financial analysts because of their solid fundamentals and potential for market outperformance.
Published: June 18, 2025
Explore BasketPotential Bargains
These companies are trading below what experts believe they're truly worth. Our analysts have carefully selected stocks with significant upside potential, representing hidden opportunities for growth as they move toward their projected valuations.
Published: June 17, 2025
Explore BasketWhy You’ll Want to Watch This Stock
Clinical Catalysts Ahead
Trial readouts and regulatory milestones can create sharp share-price moves, though outcomes are uncertain and timelines can slip.
Platform Science Focus
A prime‑boost platform aims to stimulate T‑cell immunity across indications, offering scientific potential but with clinical execution risk.
Partnerships Matter
Collaborations or licensing deals may de‑risk programmes and provide funding, yet dependence on partners and terms can affect value.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
6% Interest on Cash
Earn 6% AER on uninvested cash with daily interest payments.
